Segura J., Ruilope LM, Zanchetti A.On the importance of estimating renal function for cardiovascular risk assessment . J Hypertens2004;22:1635-9.
2.
Ruilope LMThe kidney as a sensor of cardiovascular risk in essential hypertension . J Am Soc Nephrol2002;13(suppl 3):S165-S168.
3.
Swedko PJ, Clark HD, Paramsothy K., Akbari A.Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med2003;163:356-60.
4.
Cockroft DW, Gault MHPrediction of creatinine clearance from serum creatinine. Nephron1976;16:31-41.
5.
Levey AS, Bosch J., Lewis JB, Greene T., Rogers N., Roth D.A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med1999;130:461-70.
6.
National Kidney Foundation: K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis2002;39(suppl 1):S1-S266.
7.
Ruilope LM, Salvetti A., Jamerson K. et al. Renal function and intensive lowering of blood pressure in the hypertensive subjects of the HypertensionOptimal Treatment (HOT) study. J Am Soc Nephrol2001;12:218-25.
8.
Henry RMA , Kostense PJ, Bos G. et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int2002 ;62:1402-07.
9.
Hillege HL, Fidler V., Diercks GF et al. Urinary albumin excretion predicts cardiovascular and non cardiovascular mortality in general population. Circulation2002; 106:1777-82.
10.
Wachtell K. , Olsen MH, Dahlof B. et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens2002;20:405-12.
11.
Manjunath G. , Tighiouart H., Ibrahim H. et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular disease in the community. J Am Coll Cardiol2003;41:47-55.
12.
Sowers JR, Haffner S.Treatment of cardiovascular and renal risk factors in the diabetic hypertensive . Hypertension2002;40:781-8.
13.
Morrisey K. , Evans RA, Wakefield L., Phillips AOTranslational regulation of renal proximal tubular epithelial cell transforming growth factor-beta1 generation by insulin . Am J Pathol2001:159:1905-15.
14.
Rerolle JP, Hertig A., Nguyen G., Sraer JD, Rondeau EPPlasminogen activator inhibitor type 1 is a potential target in renal fibrinogenesis . Kidney Int2000;58:1841-50.
15.
Hodge AM , Dowse GK, Zimmet PZMicroalbuminuria, cardiovascular risk factors, and insulin resistance in two populations with a high risk of type 2 diabetes mellitus. Diabet Med1996;13:441-9.
16.
Guidelines Committee.2003European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens2003;21:1011-53.
17.
Chobanian A. , Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA2003;289:2560-72.
18.
Segura J., Campo C., Ruilope LMEffect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int2004 ;6(suppl 92):S1-S5.
19.
Segura J., Campo C., Rodicio JL, Ruilope LMACE inhibitors and appearance of renal events in hypertensive patients . Hypertension2001;38:645-49.
20.
Tonelli M., Isles C., Curhan GC, Tonkin A., Pfeffer MA, Shepherd J., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation2004;110:1557-63.
21.
Grothusen C. , Bley S., Selle T. et al. Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis . Atherosclerosis2005;182(1):57-69.
22.
Curtis BM, Levin A., Parfrey PSMultiple risk factor intervention in chronic kidney disease: management of cardiac disease in chronic kidney disease patients. Med Clin North Am2005;89:511-23.
